Robert T Nolte
Overview
Explore the profile of Robert T Nolte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
938
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gillis E, Parcella K, Bowsher M, Cook J, Iwuagwu C, Naidu B, et al.
J Med Chem
. 2023 Jan;
66(3):1941-1954.
PMID: 36719971
Long-acting (LA) human immunodeficiency virus-1 (HIV-1) antiretroviral therapy characterized by a ≥1 month dosing interval offers significant advantages over daily oral therapy. However, the criteria for compounds that enter clinical...
2.
Schulte C, Deaton D, Diaz E, Do Y, Gampe R, Guss J, et al.
Bioorg Med Chem Lett
. 2021 May;
47:128113.
PMID: 33991628
Through an internal virtual screen at GlaxoSmithKline a distinct class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors were discovered. Careful evaluation of crystal structures and SAR led to a novel, potent, and orally...
3.
Pearce K, Overton L, Gampe R, Barrett G, Taylor J, McKee D, et al.
Acta Crystallogr F Struct Biol Commun
. 2019 Apr;
75(Pt 4):239-245.
PMID: 30950824
Furin, also called proprotein convertase subtilisin/kexin 3 (PCSK3), is a calcium-dependent serine endoprotease that processes a wide variety of proproteins involved in cell function and homeostasis. Dysregulation of furin has...
4.
Peese K, Allard C, Connolly T, Johnson B, Li C, Patel M, et al.
J Med Chem
. 2019 Jan;
62(3):1348-1361.
PMID: 30609350
A series of 5,6,7,8-tetrahydro-1,6-naphthyridine derivatives targeting the allosteric lens-epithelium-derived-growth-factor-p75 (LEDGF/p75)-binding site on HIV-1 integrase, an attractive target for antiviral chemotherapy, was prepared and screened for activity against HIV-1 infection in...
5.
Gupta K, Turkki V, Sherrill-Mix S, Hwang Y, Eilers G, Taylor L, et al.
PLoS Biol
. 2016 Dec;
14(12):e1002584.
PMID: 27935939
The allosteric inhibitors of integrase (termed ALLINIs) interfere with HIV replication by binding to the viral-encoded integrase (IN) protein. Surprisingly, ALLINIs interfere not with DNA integration but with viral particle...
6.
Adams P, Aertgeerts K, Bauer C, Bell J, Berman H, Bhat T, et al.
Structure
. 2016 Apr;
24(4):502-508.
PMID: 27050687
Crystallographic studies of ligands bound to biological macromolecules (proteins and nucleic acids) represent an important source of information concerning drug-target interactions, providing atomic level insights into the physical chemistry of...
7.
Wood E, Bledsoe R, Chai J, Daka P, Deng H, Ding Y, et al.
J Biol Chem
. 2015 Jun;
290(32):19681-96.
PMID: 26055709
2',5'-Oligoadenylate synthetase (OAS) enzymes and RNase-L constitute a major effector arm of interferon (IFN)-mediated antiviral defense. OAS produces a unique oligonucleotide second messenger, 2',5'-oligoadenylate (2-5A), that binds and activates RNase-L....
8.
Gupta K, Brady T, Dyer B, Malani N, Hwang Y, Male F, et al.
J Biol Chem
. 2014 Jun;
289(30):20477-88.
PMID: 24904063
HIV-1 replication in the presence of antiviral agents results in evolution of drug-resistant variants, motivating the search for additional drug classes. Here we report studies of GSK1264, which was identified...
9.
Harris P, Bandyopadhyay D, Berger S, Campobasso N, Capriotti C, Cox J, et al.
ACS Med Chem Lett
. 2014 Jun;
4(12):1238-43.
PMID: 24900635
Potent inhibitors of RIP1 kinase from three distinct series, 1-aminoisoquinolines, pyrrolo[2,3-b]pyridines, and furo[2,3-d]pyrimidines, all of the type II class recognizing a DLG-out inactive conformation, were identified from screening of our...
10.
DeAnda F, Hightower K, Nolte R, Hattori K, Yoshinaga T, Kawasuji T, et al.
PLoS One
. 2013 Oct;
8(10):e77448.
PMID: 24146996
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In...